Printer Friendly

SYVA INTRODUCES MICROTRAK XL

 PALO ALTO, Calif., Jan. 6 /PRNewswire/ -- Syva Co., the medical diagnostics business of Syntex Corp. (NYSE:SYN), has introduced the new MICROTRAK XL(R) system, the first fully automated, walkaway system available to clinical and hospital laboratories in the United States for infectious disease testing, Syva announced today.
 MICROTRAK XL will feature assays that detect hepatitis A&B, HIV 1/2, Chlamydia trachomatis, Rubella, Toxoplasma and cytomegalovirus when the complete menu of assays has been approved by the U.S. Food and Drug Administration (FDA).
 Manufactured for Syva by Bio-Tek Co. of Winooski, Vt., the MICROTRAK XL system can simultaneously run combinations of up to eight different Syva assays on a single blood sample. Working on as many as 95 samples and controls at a time, MICROTRAK XL can, within two to four hours, deliver 192 results for any combination of these samples and assays. Currently available systems are only able to run one assay at a time.
 MICROTRAK XL meets laboratory managers' needs to increase productivity and contain healthcare costs by providing assay systems that are flexible, labor-efficient and easy-to-use. The system, for example, is the first that makes it possible to consolidate the lab's hepatitis, Chlamydia and HIV testing into one fully-automated workstation. It also offers a comprehensive menu of tests at a single workstation that includes integrated data processing and management capabilities.
 With the MICROTRAK XL system, the lab technician loads into the instrument test tubes containing blood samples to be analyzed. The technician then loads the reagents, programs the system for the requested tests and walks away, free to perform other tasks. The MICROTRAK XL system automatically performs the entire set of tasks, from sample pipetting to calculation of results. In addition, while the system is running, the technician can enter patient demographic and clinical information into the MICROTRAK XL's on-board computer. This information, linked to assay results, simplifies statistical analysis and epidemiological tracking.
 In a typical manual or semi-automated instrument system, the major sources of sample misdiagnosis have been operator error and transcription error, both of which are difficult to eliminate. However, with the fully automated MICROTRAK XL system's procedural precision and accuracy, and its capability for positive sample identification, the likelihood of false results is greatly reduced.
 With the MICROTRAK XL, the technician handles a sample only once regardless of how many tests a doctor requests. Minimal handling reduces the technician's risk of exposure to infectious agents and helps prevent sample identification problems.
 During 1992, Syva introduced two new instrument systems in addition to MICROTRAK XL: the VISTA(R) Immunoassay System, which will ultimately be used to diagnose thyroid and fertility disorders, cancer and anemia, once all assays receive FDA clearance; and the SOLARIS(R) System for the European therapeutic drug monitoring (TDM) and drugs-of-abuse testing (DAT) markets.
 Sales of Syva's medical-diagnostics products in fiscal year 1992 were $211.9 million, or approximately 10 percent of Syntex Corp.'s $2,085.0 million sales for the period.
 Syva Co. is a developer, manufacturer and marketer of medical diagnostic tests and instrument systems. Syntex Corp. is an international healthcare company engaged in the research, development, manufacturing and marketing of human and animal pharmaceuticals and medical diagnostics.
 -0- 1/6/93
 /CONTACT: Linda Thomas of Syntex, 415-852-1321/
 (SYN)


CO: Syntex Corp.; Syva Co. ST: California IN: MTC SU: PDT

TM -- SJ014 -- 2236 01/06/93 13:37 EST
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Jan 6, 1993
Words:562
Previous Article:CHEVRON ADOPTS NEW ACCOUNTING STANDARDS
Next Article:LONG DISTANCE THIEVES POSING AS FEDERAL LAW ENFORCEMENT AGENTS PERPETRATE SCAMS
Topics:


Related Articles
SYVA INTRODUCES NEW AUTOMATED IMMUNODIAGNOSTIC SYSTEM
SYVA INTRODUCES NEW AUTOMATED IMMUNODIAGNOSTIC SYSTEM
INTERNATIONAL MUREX TECHNOLOGIES NAMES FORMER SYNTEX DIVISION DIRECTOR TO HEAD INTERNATIONAL COMMERCIAL OPERATIONS
BEHRING DIAGNOSTICS INC. TO ACQUIRE SYNTEX SUBSIDIARY SYVA COMPANY
OLYMPUS AMERICA, BEHRING DIAGNOSTICS TO CO-MARKET GENERAL CHEM ANALYZER AND EMIT(R) ASSAYS TO HOSPITAL LABS
Point of Care Technologies Announces 5-Year Private Label Distribution Agreement with Syva Company, a Subsidiary of Dade Behring, Inc.
Point of Care Technologies Announces 5-Year Private Label Distribution Agreement with Syva Company, a Subsidiary of Dade Behring, Inc.
Dade Behring Launches New Drugs-of-Abuse Testing Capabilities.
Dade Behring and Olympus America Announce Enhanced U.S. Marketing And Distribution Relationship.

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters